BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 28288821)

  • 21. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
    Hua W; Zhao J; Hu W; Gou S
    J Inorg Biochem; 2018 Sep; 186():17-23. PubMed ID: 29807243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells.
    Chen FH; Lu N; Zhang HW; Zhao L; He LC; Sun HP; You QD; Li ZY; Guo QL
    Mol Pharmacol; 2012 Nov; 82(5):958-71. PubMed ID: 22909797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
    Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
    Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel pyrazole-containing indolizine derivative suppresses NF-κB activation and protects against TNBS-induced colitis via a PPAR-γ-dependent pathway.
    Fu Y; Ma J; Shi X; Song XY; Yang Y; Xiao S; Li J; Gu WJ; Huang Z; Zhang J; Chen J
    Biochem Pharmacol; 2017 Jul; 135():126-138. PubMed ID: 28336257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
    Wang M; Li G; Jiang G; Cai J; Zhong W; Huang R; Liu Z; Huang X; Wang H
    Eur J Med Chem; 2024 Feb; 266():116095. PubMed ID: 38215589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z; Wang M; Wang H; Fang L; Gou S
    Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.
    Hu W; Fang L; Hua W; Gou S
    J Inorg Biochem; 2017 Oct; 175():47-57. PubMed ID: 28700961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
    Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
    Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LW-214, a newly synthesized flavonoid, induces intrinsic apoptosis pathway by down-regulating Trx-1 in MCF-7 human breast cells.
    Pan D; Li W; Miao H; Yao J; Li Z; Wei L; Zhao L; Guo Q
    Biochem Pharmacol; 2014 Feb; 87(4):598-610. PubMed ID: 24374359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H; Wang X; Gou S
    J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
    Chen F; Xu G; Tian W; Gou S
    Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum(IV) Complexes of
    Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
    Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.